StockDuty ← Dashboard Nov 02, 2026 08:36 PM ET
SignalCorporate

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

Krystal Biotech beat Q3 earnings and revenue estimates.

What happened: Krystal Biotech (KRYS) reported quarterly earnings of $2.05 per share and revenue of $127.34 million, beating the Zacks Consensus Estimates for both. Key numbers: EPS $2.05 vs. $1.84 estimate, earnings surprise +11.41%, year-ago EPS $2.66. Revenue $127.34 million vs. estimate beat of 2.16%, year-ago revenue $97.8 million. Why it matters: Despite the beat, the estimate revisions trend ahead of the release was unfavorable, translating into a Zacks Rank #5 (Strong Sell), and the shares are expected to underperform the market in the near future. Market: -12.9% today ($2.84), -56.7% YTD, 0.7x vol — as of 20:18 UTC Coverage: 4 outlets in 24h
Krystal Biotech (KRYS) reported quarterly earnings of $2.05 per share and revenue of $127.34 million, beating the Zacks Consensus Estimates for both.
Despite the beat, the estimate revisions trend ahead of the release was unfavorable, translating into a Zacks Rank #5 (Strong Sell), and the shares are expected to underperform the market in the near future. Market: -12.9% today ($2.84), -56.7% YTD, 0.7x vol — as of 20:18 UTC
Sources